Christian P Larsen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/752765/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature, 1996, 381, 434-438.	27.8	1,430
2	mTOR regulates memory CD8 T-cell differentiation. Nature, 2009, 460, 108-112.	27.8	1,346
3	Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature, 2008, 453, 667-671.	27.8	959
4	A Phase III Study of Belataceptâ€based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study). American Journal of Transplantation, 2010, 10, 535-546.	4.7	838
5	Costimulation Blockade with Belatacept in Renal Transplantation. New England Journal of Medicine, 2005, 353, 770-781.	27.0	827
6	4-1BB Costimulatory Signals Preferentially Induce CD8+ Tâ€,Cell Proliferation and Lead to the Amplification In Vivo of Cytotoxic T Cell Responses. Journal of Experimental Medicine, 1997, 186, 47-55.	8.5	710
7	Rational Development of LEA29Y (belatacept), a High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive Properties. American Journal of Transplantation, 2005, 5, 443-453.	4.7	655
8	Migration and maturation of Langerhans cells in skin transplants and explants Journal of Experimental Medicine, 1990, 172, 1483-1493.	8.5	616
9	Belatacept and Long-Term Outcomes in Kidney Transplantation. New England Journal of Medicine, 2016, 374, 333-343.	27.0	593
10	Migration of dendritic leukocytes from cardiac allografts into host spleens. A novel pathway for initiation of rejection Journal of Experimental Medicine, 1990, 171, 307-314.	8.5	539
11	Heterologous immunity provides a potent barrier to transplantation tolerance. Journal of Clinical Investigation, 2003, 111, 1887-1895.	8.2	535
12	Dendritic cell loss from nonlymphoid tissues after systemic administration of lipopolysaccharide, tumor necrosis factor, and interleukin 1 Journal of Experimental Medicine, 1995, 181, 2237-2247.	8.5	451
13	Long-term survival of neonatal porcine islets in nonhuman primates by targeting costimulation pathways. Nature Medicine, 2006, 12, 304-306.	30.7	439
14	Asialo GM1+ CD8+ T cells play a critical role in costimulation blockade–resistant allograft rejection. Journal of Clinical Investigation, 1999, 104, 1715-1722.	8.2	329
15	CD40-gp39 INTERACTIONS PLAY A CRITICAL ROLE DURING ALLOGRAFT REJECTION. Transplantation, 1996, 61, 4-9.	1.0	308
16	Functional expression of the costimulatory molecule, B7/BB1, on murine dendritic cell populations Journal of Experimental Medicine, 1992, 176, 1215-1220.	8.5	284
17	Heterologous immunity provides a potent barrier to transplantation tolerance. Journal of Clinical Investigation, 2003, 111, 1887-1895.	8.2	283
18	Three-Year Outcomes from BENEFIT, a Randomized, Active-Controlled, Parallel-Group Study in Adult Kidney Transplant Recipients. American Journal of Transplantation, 2012, 12, 210-217.	4.7	280

#	Article	IF	CITATIONS
19	TRANSPLANTATION TOLERANCE INDUCED BY CTLA4-Ig1. Transplantation, 1994, 57, 1701-1705.	1.0	277
20	Cytokine gene transcription in vascularised organ grafts: analysis using semiquantitative polymerase chain reaction Journal of Experimental Medicine, 1991, 174, 493-496.	8.5	271
21	Cutting Edge: Administration of Anti-CD40 Ligand and Donor Bone Marrow Leads to Hemopoietic Chimerism and Donor-Specific Tolerance Without Cytoreductive Conditioning. Journal of Immunology, 2000, 165, 1-4.	0.8	239
22	Heterologous immunity: an overlooked barrier to tolerance. Immunological Reviews, 2003, 196, 147-160.	6.0	214
23	Viral targeting of fibroblastic reticular cells contributes to immunosuppression and persistence during chronic infection. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 15430-15435.	7.1	206
24	Transplanting the Highly Sensitized Patient: The Emory Algorithm. American Journal of Transplantation, 2006, 6, 2307-2315.	4.7	192
25	Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates. Nature Medicine, 2009, 15, 746-749.	30.7	183
26	Role of CD28-B7 Interactions in Generation and Maintenance of CD8 T Cell Memory. Journal of Immunology, 2001, 167, 5565-5573.	0.8	180
27	Preâ€ŧransplant antibody screening and anti D154 costimulation blockade promote longâ€ŧerm xenograft survival in a pigâ€ŧoâ€primate kidney transplant model. Xenotransplantation, 2015, 22, 221-230.	2.8	178
28	Development of a Chimeric Anti-CD40 Monoclonal Antibody That Synergizes with LEA29Y to Prolong Islet Allograft Survival. Journal of Immunology, 2005, 174, 542-550.	0.8	177
29	Five-Year Safety and Efficacy of Belatacept in Renal Transplantation. Journal of the American Society of Nephrology: JASN, 2010, 21, 1587-1596.	6.1	177
30	The CD40 pathway in allograft rejection, acceptance, and tolerance. Current Opinion in Immunology, 1997, 9, 641-647.	5.5	176
31	Continuous recruitment of naive T cells contributes to heterogeneity of antiviral CD8 T cells during persistent infection. Journal of Experimental Medicine, 2006, 203, 2263-2269.	8.5	169
32	Calcineurin Inhibitor-Free CD28 Blockade-Based Protocol Protects Allogeneic Islets in Nonhuman Primates. Diabetes, 2002, 51, 265-270.	0.6	165
33	Belatacept-Based Regimens Versus a Cyclosporine A-Based Regimen in Kidney Transplant Recipients: 2-Year Results From the BENEFIT and BENEFIT-EXT Studies. Transplantation, 2010, 90, 1528-1535.	1.0	156
34	Costimulation Blockade, Busulfan, and Bone Marrow Promote Titratable Macrochimerism, Induce Transplantation Tolerance, and Correct Genetic Hemoglobinopathies with Minimal Myelosuppression. Journal of Immunology, 2001, 167, 1103-1111.	0.8	148
35	Belatacept-Based Regimens Are Associated With Improved Cardiovascular and Metabolic Risk Factors Compared With Cyclosporine in Kidney Transplant Recipients (BENEFIT and BENEFIT-EXT Studies). Transplantation, 2011, 91, 976-983.	1.0	148
36	Microchimerism and rejection in clinical transplantation. Lancet, The, 1997, 349, 1358-1360.	13.7	147

#	Article	IF	CITATIONS
37	Anti-CD40 therapy extends renal allograft survival in rhesus macaques1. Transplantation, 2002, 74, 933-940.	1.0	147
38	INDUCTION OF TRANSPLANTATION TOLERANCE IN ADULTS USING DONOR ANTIGEN AND ANTI-CD4 MONOCLONAL ANTIBODY. Transplantation, 1992, 54, 475-482.	1.0	145
39	CD40-Specific Costimulation Blockade Enhances Neonatal Porcine Islet Survival in Nonhuman Primates. American Journal of Transplantation, 2011, 11, 947-957.	4.7	137
40	Islet Xenotransplantation Using Gal-Deficient Neonatal Donors Improves Engraftment and Function. American Journal of Transplantation, 2011, 11, 2593-2602.	4.7	136
41	Long-term survival of pig-to-rhesus macaque renal xenografts is dependent on CD4 T cell depletion. American Journal of Transplantation, 2019, 19, 2174-2185.	4.7	136
42	A New Look at Blockade of T-cell Costimulation: A Therapeutic Strategy for Long-term Maintenance Immunosuppression. American Journal of Transplantation, 2006, 6, 876-883.	4.7	135
43	Genetic Characterization of Strain Differences in the Ability to Mediate CD40/CD28-Independent Rejection of Skin Allografts. Journal of Immunology, 2000, 165, 6849-6857.	0.8	128
44	MIGRATION PATTERNS OF DENDRITIC LEUKOCYTES. Transplantation, 1990, 49, 1-7.	1.0	126
45	4-1BB Costimulation Is Required for Protective Anti-Viral Immunity After Peptide Vaccination. Journal of Immunology, 2000, 164, 2320-2325.	0.8	126
46	Antigen-specific precursor frequency impacts T cell proliferation, differentiation, and requirement for costimulation. Journal of Experimental Medicine, 2007, 204, 299-309.	8.5	119
47	Translating costimulation blockade to the clinic: lessons learned from three pathways. Immunological Reviews, 2009, 229, 294-306.	6.0	119
48	Selective Targeting of Human Alloresponsive CD8+ Effector Memory T Cells Based on CD2 Expression. American Journal of Transplantation, 2011, 11, 22-33.	4.7	118
49	CTLA4-Ig PLUS BONE MARROW INDUCES LONG-TERM ALLOGRAFT SURVIVAL AND DONOR-SPECIFIC UNRESPONSIVENESS IN THE MURINE MODEL. Transplantation, 1996, 61, 997-1004.	1.0	115
50	PROLONGED ACCEPTANCE OF CONCORDANT AND DISCORDANT XENOGRAFTS WITH COMBINED CD40 AND CD28 PATHWAY BLOCKADE1. Transplantation, 1998, 65, 1422-1428.	1.0	113
51	Cytokine Gene Expression: Analysis using Northern Blotting, Polymerase Chain Reaction and in situ Hybridization. Immunological Reviews, 1991, 119, 163-179.	6.0	109
52	GENE EXPRESSION ANALYSIS IN HUMAN RENAL ALLOGRAFT BIOPSY SAMPLES USING HIGH-DENSITY OLIGOARRAY TECHNOLOGY1. Transplantation, 2001, 72, 948-953.	1.0	108
53	Dynamic Regulation of T Cell Immunity by CD43. Journal of Immunology, 2002, 168, 6022-6031.	0.8	108
54	An Integrated Safety Profile Analysis of Belatacept in Kidney Transplant Recipients. Transplantation, 2010, 90, 1521-1527.	1.0	108

#	Article	IF	CITATIONS
55	LFA-1–specific therapy prolongs allograft survival in rhesus macaques. Journal of Clinical Investigation, 2010, 120, 4520-4531.	8.2	106
56	Cutting Edge: Rapamycin Augments Pathogen-Specific but Not Graft-Reactive CD8+ T Cell Responses. Journal of Immunology, 2010, 185, 2004-2008.	0.8	106
5 7	Decreased incidence of NSF in patients on dialysis after changing gadolinium contrastâ€enhanced MRI protocols. Journal of Magnetic Resonance Imaging, 2010, 31, 440-446.	3.4	102
58	Cutting Edge: Persistent Viral Infection Prevents Tolerance Induction and Escapes Immune Control Following CD28/CD40 Blockade-Based Regimen. Journal of Immunology, 2002, 169, 5387-5391.	0.8	98
59	Experience with a Novel Efalizumabâ€Based Immunosuppressive Regimen to Facilitate Single Donor Islet Cell Transplantation. American Journal of Transplantation, 2010, 10, 2082-2091.	4.7	98
60	InÂVivo T Cell Costimulation Blockade with Abatacept forÂAcute Graft-versus-Host Disease Prevention: A First-in-Disease Trial. Biology of Blood and Marrow Transplantation, 2013, 19, 1638-1649.	2.0	96
61	Innate Immune Responses to Transplants. Immunity, 2001, 14, 369-376.	14.3	95
62	Sirolimus Enhances the Magnitude and Quality of Viral-Specific CD8+ T-Cell Responses to Vaccinia Virus Vaccination in Rhesus Macaques. American Journal of Transplantation, 2011, 11, 613-618.	4.7	94
63	The Impact of Renal Function on Outcomes of Bariatric Surgery. Journal of the American Society of Nephrology: JASN, 2012, 23, 885-894.	6.1	93
64	Engraftment of Adult Porcine Islet Xenografts in Diabetic Nonhuman Primates Through Targeting of Costimulation Pathways. American Journal of Transplantation, 2007, 7, 2260-2268.	4.7	87
65	Characterization of Virus-Mediated Inhibition of Mixed Chimerism and Allospecific Tolerance. Journal of Immunology, 2001, 167, 4987-4995.	0.8	86
66	Belatacept Combined With Transient Calcineurin Inhibitor Therapy Prevents Rejection and Promotes Improved Long-Term Renal Allograft Function. American Journal of Transplantation, 2017, 17, 2922-2936.	4.7	86
67	Costimulation Blockade in Autoimmunity and Transplantation: The CD28 Pathway. Journal of Immunology, 2016, 197, 2045-2050.	0.8	83
68	FAS-MEDIATED CYTOTOXICITY AN IMMUNOEFFECTOR OR IMMUNOREGULATORY PATHWAY IN T CELL-MEDIATED IMMUNE RESPONSES?. Transplantation, 1995, 60, 221-224.	1.0	82
69	Antigen-specific induced Foxp3 ⁺ regulatory T cells are generated following CD40/CD154 blockade. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 20701-20706.	7.1	82
70	The Role of Graft-derived Dendritic Leukocytes in the Rejection of Vascularized Organ Allografts. Annals of Surgery, 1990, 212, 308-317.	4.2	78
71	ANALYSIS OF THE B7 COSTIMULATORY PATHWAY IN ALLOGRAFT REJECTION1. Transplantation, 1997, 63, 1463-1469.	1.0	77
72	Transplant Tolerance in Non-Human Primates: Progress, Current Challenges and Unmet Needs. American Journal of Transplantation, 2006, 6, 884-893.	4.7	75

#	Article	IF	CITATIONS
73	NK Cells Mediate Costimulation Blockade-Resistant Rejection of Allogeneic Stem Cells During Nonmyeloablative Transplantation. American Journal of Transplantation, 2006, 6, 292-304.	4.7	74
74	A Novel Monoclonal Antibody to CD40 Prolongs Islet Allograft Survival. American Journal of Transplantation, 2012, 12, 2079-2087.	4.7	74
75	Vigorous Allograft Rejection in the Absence of Danger. Journal of Immunology, 2000, 164, 3065-3071.	0.8	73
76	Anti-CD40 Monoclonal Antibody Synergizes with CTLA4-Ig in Promoting Long-Term Graft Survival in Murine Models of Transplantation. Journal of Immunology, 2009, 183, 1625-1635.	0.8	73
77	Integrin Antagonists Prevent Costimulatory Blockade-Resistant Transplant Rejection by CD8+ Memory T Cells. American Journal of Transplantation, 2012, 12, 69-80.	4.7	72
78	A cure for murine sickle cell disease through stable mixed chimerism and tolerance induction after nonmyeloablative conditioning and major histocompatibility complex–mismatched bone marrow transplantation. Blood, 2002, 99, 1840-1849.	1.4	71
79	Late Priming and Variability of Epitope-Specific CD8+ T Cell Responses during a Persistent Virus Infection. Journal of Immunology, 2005, 174, 7950-7960.	0.8	70
80	Alternative Immunomodulatory Strategies for Xenotransplantation: CD40/154 Pathway-Sparing Regimens Promote Xenograft Survival. American Journal of Transplantation, 2012, 12, 1765-1775.	4.7	70
81	Multiple Combination Therapies Involving Blockade of ICOS/B7RP-1 Costimulation Facilitate Long-Term Islet Allograft Survival. American Journal of Transplantation, 2004, 4, 526-536.	4.7	68
82	GVHD after haploidentical transplantation: a novel, MHC-defined rhesus macaque model identifies CD28â^ CD8+ T cells as a reservoir of breakthrough T-cell proliferation during costimulation blockade and sirolimus-based immunosuppression. Blood, 2010, 116, 5403-5418.	1.4	67
83	Measuring symptom experience of side-effects of immunosuppressive drugs: the Modified Transplant Symptom Occurrence and Distress Scale. Transplant International, 2008, 21, 764-773.	1.6	66
84	Induction of Chimerism in Rhesus Macaques through Stem Cell Transplant and Costimulation Blockade-Based Immunosuppression. American Journal of Transplantation, 2007, 7, 320-335.	4.7	65
85	Nondepleting Anti-CD40-Based Therapy Prolongs Allograft Survival in Nonhuman Primates. American Journal of Transplantation, 2012, 12, 126-135.	4.7	65
86	Role of 4-1BB in Allograft Rejection Mediated by CD8+ T Cells. American Journal of Transplantation, 2003, 3, 543-551.	4.7	64
87	Immune responsiveness and protective immunity after transplantation. Transplant International, 2008, 21, 293-303.	1.6	64
88	Impaired Recall of CD8 Memory T Cells in Immunologically Privileged Tissue. Journal of Immunology, 2005, 174, 1165-1170.	0.8	57
89	Chimerism and cure: hematologic and pathologic correction of murine sickle cell disease. Blood, 2003, 102, 4582-4593.	1.4	56
90	Effect of the iChoose Kidney decision aid in improving knowledge about treatment options among transplant candidates: A randomized controlled trial. American Journal of Transplantation, 2018, 18, 1954-1965.	4.7	56

#	Article	IF	CITATIONS
91	The Role of the IL-2 Pathway in Costimulation Blockade-Resistant Rejection of Allografts. Journal of Immunology, 2002, 168, 1123-1130.	0.8	54
92	Prevention of Chronic Rejection in Murine Cardiac Allografts: A Comparison of Chimerism- and Nonchimerism-Inducing Costimulation Blockade-Based Tolerance Induction Regimens. Journal of Immunology, 2002, 169, 2677-2684.	0.8	54
93	CD40 Blockade Combines with CTLA4Ig and Sirolimus to Produce Mixed Chimerism in an MHC-Defined Rhesus Macaque Transplant Model. American Journal of Transplantation, 2012, 12, 115-125.	4.7	54
94	The Role of TNF Receptor and TNF Superfamily Molecules in Organ Transplantation. American Journal of Transplantation, 2002, 2, 12-18.	4.7	51
95	Infusion of Stably Immature Monocyte-Derived Dendritic Cells Plus CTLA4Ig Modulates Alloimmune Reactivity in Rhesus Macaques. Transplantation, 2007, 84, 196-206.	1.0	51
96	An MHC-Defined Primate Model Reveals Significant Rejection of Bone Marrow After Mixed Chimerism Induction Despite Full MHC Matching. American Journal of Transplantation, 2010, 10, 2396-2409.	4.7	50
97	PD-1-Dependent Mechanisms Maintain Peripheral Tolerance of Donor-Reactive CD8+ T Cells to Transplanted Tissue. Journal of Immunology, 2008, 181, 5313-5322.	0.8	48
98	IDENTIFICATION OF DONOR-DERIVED DENDRITIC CELL PROGENITORS IN BONE MARROW OF SPONTANEOUSLY TOLERANT LIVER ALLOGRAFT RECIPIENTS1,2. Transplantation, 1995, 60, 1555-1559.	1.0	47
99	CD8 T CELL-MEDIATED REJECTION OF INTESTINAL ALLOGRAFTS IS RESISTANT TO INHIBITION OF THE CD40/CD154 COSTIMULATORY PATHWAY. Transplantation, 2001, 71, 1351-1354.	1.0	47
100	Regulatory T Cells Exhibit Decreased Proliferation but Enhanced Suppression After Pulsing With Sirolimus. American Journal of Transplantation, 2012, 12, 1441-1457.	4.7	46
101	CTLA4Ig Prevents Alloantibody Formation Following Nonhuman Primate Islet Transplantation Using the CD40-Specific Antibody 3A8. American Journal of Transplantation, 2012, 12, 1918-1923.	4.7	44
102	Overcoming the memory barrier in tolerance induction: molecular mimicry and functional heterogeneity among pathogen-specific T-cell populations. Current Opinion in Organ Transplantation, 2010, 15, 405-410.	1.6	43
103	Tolerance Assays: Measuring the Unknown. Transplantation, 2006, 81, 1503-1509.	1.0	42
104	CMV high-risk status and posttransplant outcomes in kidney transplant recipients treated with belatacept. American Journal of Transplantation, 2021, 21, 208-221.	4.7	42
105	Low-Affinity Memory CD8+ T Cells Mediate Robust Heterologous Immunity. Journal of Immunology, 2016, 196, 2838-2846.	0.8	41
106	Blockade of T cell costimulation reveals interrelated actions of CD4+ and CD8+ T cells in control of SIV replication. Journal of Clinical Investigation, 2004, 113, 836-845.	8.2	41
107	NK Cells Rapidly Reject Allogeneic Bone Marrow in the Spleen Through a Perforin―and Ly49Dâ€Dependent, but NKG2Dâ€Independent Mechanism. American Journal of Transplantation, 2007, 7, 1884-1896.	4.7	40
108	Donor-Reactive T-Cell Stimulation History and Precursor Frequency: Barriers to Tolerance Induction. Transplantation, 2009, 87, S69-S74.	1.0	40

#	Article	IF	CITATIONS
109	SYSTEMIC LIPOPOLYSACCHARIDE RECRUITS DENDRITIC CELL PROGENITORS TO NONLYMPHOID TISSUES. Transplantation, 1995, 59, 1319-1324.	1.0	40
110	CD122 signaling in CD8+ memory T cells drives costimulation-independent rejection. Journal of Clinical Investigation, 2018, 128, 4557-4572.	8.2	40
111	CTLA4Ig combined with anti-LFA-1 prolongs cardiac allograft survival indefinitely. Transplant Immunology, 2002, 10, 55-61.	1.2	39
112	A Mouse Model for Polyomavirus-Associated Nephropathy of Kidney Transplants. American Journal of Transplantation, 2006, 6, 913-922.	4.7	39
113	Glial Cell Line-Derived Neurotrophic Factor Increases β-Cell Mass and Improves Glucose Tolerance. Gastroenterology, 2008, 134, 727-737.	1.3	39
114	TRANSPLANTATION OF THE BONE MARROW MICROENVIRONMENT LEADS TO HEMATOPOIETIC CHIMERISM WITHOUT CYTOREDUCTIVE CONDITIONING1. Transplantation, 2000, 69, 2491-2496.	1.0	36
115	Longâ€Term Survival of Intestinal Allografts Induced by Costimulation Blockade, Busulfan and Donor Bone Marrow Infusion. American Journal of Transplantation, 2003, 3, 1091-1098.	4.7	34
116	LFA-1 blockade induces effector and regulatory T-cell enrichment in lymph nodes and synergizes with CTLA-4lg to inhibit effector function. Blood, 2011, 118, 5851-5861.	1.4	34
117	Costimulation Requirements for Antiviral CD8+ T Cells Differ for Acute and Persistent Phases of Polyoma Virus Infection. Journal of Immunology, 2006, 176, 1814-1824.	0.8	33
118	Role of CD28 in fatal autoimmune disorder in scurfy mice. Blood, 2007, 110, 1199-1206.	1.4	33
119	Pathogenic virus-specific T cells cause disease during treatment with the calcineurin inhibitor FK506: implications for transplantation. Journal of Experimental Medicine, 2010, 207, 2355-2367.	8.5	33
120	Transplant Tolerance: Converging on a Moving Target. Transplantation, 2006, 81, 1-6.	1.0	32
121	CD28/CD154 Blockade Prevents Autoimmune Diabetes by Inducing Nondeletional Tolerance After Effector T-Cell Inhibition and Regulatory T-Cell Expansion. Diabetes, 2008, 57, 2672-2683.	0.6	32
122	Limiting the Amount and Duration of Antigen Exposure during Priming Increases Memory T Cell Requirement for Costimulation during Recall. Journal of Immunology, 2011, 186, 2033-2041.	0.8	32
123	Blockade of T cell costimulation reveals interrelated actions of CD4+ and CD8+ T cells in control of SIV replication. Journal of Clinical Investigation, 2004, 113, 836-845.	8.2	32
124	Expansion of Effector Memory TCR Vβ4+CD8+ T Cells Is Associated with Latent Infection-Mediated Resistance to Transplantation Tolerance. Journal of Immunology, 2008, 180, 3190-3200.	0.8	31
125	Anti-lymphocyte function-associated antigen-1 monoclonal antibody inhibits CD40 ligand-independent immune responses and prevents chronic vasculopathy in CD40 ligand-deficient mice1. Transplantation, 2002, 74, 35-41.	1.0	29
126	Kidney transplantation: Structural and functional evaluation using MR Nephroâ€Urography. Journal of Magnetic Resonance Imaging, 2008, 28, 805-822.	3.4	29

#	Article	IF	CITATIONS
127	Dynamics of Human Regulatory T Cells in Lung Lavages of Lung Transplant Recipients. Transplantation, 2009, 88, 521-527.	1.0	29
128	Regulatory T cells in lung transplantation—an emerging concept. Seminars in Immunopathology, 2011, 33, 117-127.	6.1	29
129	Patients, Pathogens, and Protective Immunity: The Relevance of Virus-Induced Alloreactivity in Transplantation. Journal of Immunology, 2006, 176, 2691-2696.	0.8	28
130	FAILURE OF MATURE DENDRITIC CELLS OF THE HOST TO MIGRATE FROM THE BLOOD INTO CARDIAC OR SKIN ALLOGRAFTS. Transplantation, 1990, 50, 294-300.	1.0	27
131	A Critical Precursor Frequency of Donor-Reactive CD4+ T Cell Help Is Required for CD8+ T Cell-Mediated CD28/CD154-Independent Rejection. Journal of Immunology, 2008, 180, 7203-7211.	0.8	27
132	Analysis of a single-center experience with mycophenolate mofetil based immunosuppression in renal transplantation. Clinical Transplantation, 2000, 14, 413-420.	1.6	26
133	Primary and Secondary Immunocompetence in Mixed Allogeneic Chimeras. Journal of Immunology, 2003, 170, 2382-2389.	0.8	26
134	Simultaneous inhibition of B7 and LFA-1 signaling prevents rejection of discordant neural xenografts in mice lacking CD40L. Xenotransplantation, 2002, 9, 68-76.	2.8	25
135	Expanded Nonhuman Primate Tregs Exhibit a Unique Gene Expression Signature and Potently Downregulate Alloimmune Responses. American Journal of Transplantation, 2008, 8, 2252-2264.	4.7	25
136	Nonhuman Primate Transplant Models Finally Evolve: Detailed Immunogenetic Analysis Creates New Models and Strengthens the Old. American Journal of Transplantation, 2012, 12, 812-819.	4.7	25
137	CTLA4IG INDUCES LONG-TERM GRAFT SURVIVAL OF ALLOGENEIC SKIN GRAFTS AND TOTALLY INHIBITS T-CELL PROLIFERATION IN LFA-1???DEFICIENT MICE. Transplantation, 2002, 73, 293-297.	1.0	25
138	Induction of operational tolerance to discordant dopaminergic porcine xenografts1. Transplantation, 2003, 75, 1448-1454.	1.0	24
139	Cumulative Exposure to Gamma Interferon-Dependent Chemokines CXCL9 and CXCL10 Correlates with Worse Outcome After Lung Transplant. American Journal of Transplantation, 2012, 12, 438-446.	4.7	24
140	Abatacept as rescue immunosuppression after calcineurin inhibitor treatment failure in renal transplantation. American Journal of Transplantation, 2019, 19, 2342-2349.	4.7	23
141	Conventional Immunosuppression is Compatible with Costimulation Blockadeâ€Based, Mixed Chimerism Tolerance Induction. American Journal of Transplantation, 2003, 3, 895-901.	4.7	22
142	Intravital microscopy identifies selectins that regulate T cell traffic into allografts. Journal of Clinical Investigation, 2003, 112, 1714-1723.	8.2	21
143	IFN-Î ³ Dictates Allograft Fate via Opposing Effects on the Graft and on Recipient CD8 T Cell Responses. Journal of Immunology, 2009, 182, 225-233.	0.8	21
144	Evidence for Kidney Rejection After Combined Bone Marrow and Renal Transplantation Despite Ongoing Whole-Blood Chimerism in Rhesus Macaques. American Journal of Transplantation, 2012, 12, 1755-1764.	4.7	21

#	Article	IF	CITATIONS
145	The role of CD40L in T cell-dependent nitric oxide production by murine macrophages. Transplant Immunology, 2000, 8, 195-202.	1.2	20
146	Kinetics of antibody response to influenza vaccination in renal transplant recipients. Transplant Immunology, 2019, 53, 51-60.	1.2	20
147	Ebola Virus Disease: Experience and Decision Making for the First Patients outside of Africa. PLoS Medicine, 2015, 12, e1001857.	8.4	20
148	Prolongation of Murine Cardiac Allograft Survival by Microspheres Containing TNFα and IL1-β Neutralizing Antibodies. Journal of Drug Targeting, 1995, 3, 311-315.	4.4	19
149	The impact of belatacept on third-party HLA alloantibodies in highly sensitized kidney transplant recipients. American Journal of Transplantation, 2020, 20, 573-581.	4.7	19
150	Simultaneous Pancreas-Kidney Transplantation Utilizing a Common Arterial Conduit: Early Experience and Potential Applications. American Journal of Transplantation, 2003, 3, 1440-1443.	4.7	18
151	Transient CD86 Expression on Hepatitis C Virus-Specific CD8+ T Cells in Acute Infection Is Linked to Sufficient IL-2 Signaling. Journal of Immunology, 2010, 184, 2410-2422.	0.8	18
152	Optimization of de novo belatacept-based immunosuppression administered to renal transplant recipients. American Journal of Transplantation, 2021, 21, 1691-1698.	4.7	18
153	Conventional immunosuppression and co-stimulation blockade. Philosophical Transactions of the Royal Society B: Biological Sciences, 2001, 356, 703-705.	4.0	17
154	Fully MHC-Disparate Mixed Hemopoietic Chimeras Show Specific Defects in the Control of Chronic Viral Infections. Journal of Immunology, 2007, 179, 2616-2626.	0.8	17
155	The Use of Microbiome Restoration Therapeutics to Eliminate Intestinal Colonization With Multidrug-Resistant Organisms. American Journal of the Medical Sciences, 2018, 356, 433-440.	1.1	17
156	CD45RB Status of CD8+ T Cell Memory Defines T Cell Receptor Affinity and Persistence. Cell Reports, 2020, 30, 1282-1291.e5.	6.4	17
157	ANALYSIS OF THE CD40 AND CD28 PATHWAYS ON ALLOIMMUNE RESPONSES BY CD4+ T CELLS IN VIVO1. Transplantation, 2001, 72, 1286-1292.	1.0	17
158	Miles to Goâ \in . American Journal of Transplantation, 2011, 11, 1119-1120.	4.7	16
159	Avoidance of CNI and steroids using belatacept—Results of the Clinical Trials in Organ Transplantation 16 trial. American Journal of Transplantation, 2020, 20, 3599-3608.	4.7	16
160	Implications of defective immune responses in SARS-CoV-2–vaccinated organ transplant recipients. Science Immunology, 2021, 6, .	11.9	16
161	Immunosuppressive and Trafficking Properties of Donor Splenic and Bone Marrow Dendritic Cells. Transplantation, 2006, 81, 455-462.	1.0	15
162	CMV Status Drives Distinct Trajectories of CD4+ T Cell Differentiation. Frontiers in Immunology, 2021, 12, 620386.	4.8	15

#	Article	IF	CITATIONS
163	Heterologous Immunity Triggered by a Single, Latent Virus in Mus musculus: Combined Costimulation- and Adhesion- Blockade Decrease Rejection. PLoS ONE, 2013, 8, e71221.	2.5	14
164	Glial Cell Line–Derived Neurotrophic Factor Enhances Human Islet Posttransplantation Survival. Transplantation, 2011, 92, 745-751.	1.0	13
165	Integrin antagonists for transplant immunosuppression: panacea or peril?. Immunotherapy, 2011, 3, 305-307.	2.0	13
166	Emergency department use among kidney transplant recipients in the United States. American Journal of Transplantation, 2018, 18, 868-880.	4.7	13
167	Surgical Correction of Gastroesophageal Reflux in Lung Transplant Patients Is Associated With Decreased Effector CD8 Cells in Lung Lavages. Chest, 2010, 138, 937-943.	0.8	12
168	Transplantation Tolerance: Memories That Haunt Us. Science Translational Medicine, 2011, 3, 86ps22.	12.4	12
169	Apoptotic Donor Leukocytes Limit Mixed-Chimerism Induced by CD40-CD154 Blockade in Allogeneic Bone Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2006, 12, 1239-1249.	2.0	11
170	Belatacept and Basiliximab Diminish Human Antiporcine Xenoreactivity and Synergize to Inhibit Alloimmunity. Transplantation, 2008, 85, 118-124.	1.0	11
171	Interruption of OX40L signaling prevents costimulation blockade–resistant allograft rejection. JCI Insight, 2017, 2, e90317.	5.0	11
172	Every 2-month belatacept maintenance therapy in kidney transplant recipients greater than 1-year posttransplant: A randomized, noninferiority trial. American Journal of Transplantation, 2021, 21, 3066-3076.	4.7	11
173	Aggressive skin allograft rejection in CD28â^'/â^' mice independent of the CD40/CD40L costimulatory pathway. Transplant Immunology, 2001, 9, 13-17.	1.2	10
174	Belatacept and CD28 Costimulation Blockade: Preventing and Reducing Alloantibodies over the Long Term. Current Transplantation Reports, 2019, 6, 277-284.	2.0	10
175	CO-STIMULATION BLOCKADE WITH LEA29Y IN A CALCINEURIN INHIBITOR FREE MAINTENANCE REGIMEN IN RENAL TRANSPLANT: 6-MONTH EFFICACY AND SAFETY. Transplantation, 2004, 78, 264-265.	1.0	9
176	SVR Angiosarcomas can be Rejected by CD4 Costimulation Dependent and CD8 Costimulation Independent Pathways. Molecular Medicine, 2002, 8, 551-558.	4.4	8
177	Immunosuppressive protocols for pig-to-human islet transplantation: lessons from pre-clinical non-human primate models. Xenotransplantation, 2008, 15, 107-111.	2.8	8
178	Immunogenetic Management Software: a new tool for visualization and analysis of complex immunogenetic datasets. Immunogenetics, 2012, 64, 329-336.	2.4	8
179	Outcomes at 7Âyears postâ€ŧransplant in black vs nonblack kidney transplant recipients administered belatacept or cyclosporine in <scp>BENEFIT</scp> and <scp>BENEFIT</scp> â€ <scp>EXT</scp> . Clinical Transplantation, 2018, 32, e13225.	1.6	8
180	Temporal trends and current use of de novo belatacept in kidney transplant recipients in the United States. Clinical Transplantation, 2021, , e14531.	1.6	8

#	Article	IF	CITATIONS
181	Blockade of the CD40 pathway fails to prevent CD8 T cell-mediated intestinal allograft rejection. Transplantation Proceedings, 2001, 33, 418-420.	0.6	7
182	FasL IS IMPORTANT IN COSTIMULATION BLOCKADE-RESISTANT SKIN GRAFT REJECTION. Transplantation, 2001, 71, 537-543.	1.0	7
183	Toward Transplantation Tolerance: A Large Step on a Long Road. American Journal of Transplantation, 2006, 6, 1989-1990.	4.7	7
184	Transplantation Tolerance. Seminars in Nephrology, 2007, 27, 487-497.	1.6	7
185	High-Frequency Alloreactive T Cells Augment Effector Function of Low-Frequency CD8+ T-Cell Responses Under CD28/CD154 Blockade. Transplantation, 2010, 89, 1208-1217.	1.0	7
186	Enhanced Requirement for TNFR2 in Graft Rejection Mediated by Low-Affinity Memory CD8+ T Cells during Heterologous Immunity. Journal of Immunology, 2016, 197, 2009-2015.	0.8	7
187	Fecal Microbiota Transplantation Donor Screening Updates and Research Gaps for Solid Organ Transplant Recipients. Journal of Clinical Microbiology, 2021, , JCM0016121.	3.9	7
188	Cumulative Exposure to CD8+ Granzyme Bhi T Cells Is Associated with Reduced Lung Function Early after Lung Transplantation. Transplantation Proceedings, 2011, 43, 3892-3898.	0.6	6
189	Induction of Chimerism and Tolerance Using Freshly Purified or Cultured Hematopoietic Stem Cells in Nonmyeloablated Mice. , 2005, 109, 459-468.		5
190	Successful outcome after early combined liver and <i>en bloc</i> â€kidney transplant in an infant with primary hyperoxaluria type 1: A case report. Pediatric Transplantation, 2009, 13, 940-942.	1.0	5
191	BELATACEPT VS CYCLOSPORINE IN ECD KIDNEY TRANSPLANTS: TWO-YEAR OUTCOMES FROM THE BENEFIT-EXT STUDY. Transplantation, 2010, 90, 157.	1.0	5
192	Belatacept Conversion in Kidney After Liver Transplantation. Transplantation Direct, 2021, 7, e780.	1.6	5
193	hlaR: A rapid and reproducible tool to identify eplet mismatches between transplant donors and recipients. Human Immunology, 2022, 83, 248-255.	2.4	5
194	DELAYED URINARY BLADDER LEAK AFTER COMBINED KIDNEY-PANCREAS TRANSPLANTATION ASSOCIATION WITH PENILE PROSTHESIS IMPLANTATION. Transplantation, 1995, 60, 624.	1.0	4
195	Allogeneic Parenchymal and Hematopoietic Tissues Differ in Their Ability to Induce Deletion of Donor-Reactive T Cells. American Journal of Transplantation, 2003, 3, 1520-1530.	4.7	4
196	Enhanced immunosuppression induced by targeted mutation of cytotoxic T lymphocyte antigen 4-immunoglobulin. Current Opinion in Organ Transplantation, 2005, 10, 265-269.	1.6	4
197	Antigenic Disparity Impacts Outcome of Agonism but Not Blockade of Costimulatory Pathways in Experimental Transplant Models. American Journal of Transplantation, 2007, 7, 1471-1481.	4.7	4
198	Patient Navigators in Transplantation—Where Do We Go From Here?. Transplantation, 2019, 103, 1076-1077.	1.0	4

#	Article	IF	CITATIONS
199	PROLONGATION OF RENAL ALLOGRAFT SURVIVAL WITH BLOCKADE OF THE CD28 PATHWAY USING A NOVEL MUTANT CTLA4-IG FUSION PROTEIN IN NON-HUMAN PRIMATES Transplantation, 2000, 69, S123.	1.0	3
200	Interpreting murine tolerance experiments. Current Opinion in Organ Transplantation, 2000, 5, 103-107.	1.6	3
201	THE CD134/CD134L PATHWAY IS CRITICAL IN CD8-MEDIATED COSTIMULATION BLOCKADE RESISTANT REJECTION Transplantation, 2004, 78, 181.	1.0	3
202	Alloimmunity: No Toll Exemption. American Journal of Transplantation, 2007, 7, 3-4.	4.7	3
203	SAFETY PROFILE OF BELATACEPT IN KIDNEY TRANSPLANT RECIPIENTS FROM A POOLED ANALYSIS OF PHASE II AND PHASE III STUDIES. Transplantation, 2010, 90, 156.	1.0	3
204	CD28 blockade induces division-dependent downregulation of interleukin-2 receptor alpha. Transplant Immunology, 2011, 24, 94-99.	1.2	3
205	Belatacept. , 2014, , 314-319.		3
206	ADMINISTRATION OF REPEATED DOSES OF ANTI-CD40L AND DONOR BONE MARROW LEADS TO HEMATOPOIETIC CHIMERISM AND DONOR SPECIFIC TOLERANCE WITHOUT CYTOREDUCTIVE CONDITIONING Transplantation, 2000, 69, S240.	1.0	2
207	PROLONGATION OF RENAL ALLOGRAFT SURVIVAL BY A CHIMERIC ANTI-HUMAN CD40 MONOCLONAL ANTIBODY IN NONHUMAN PRIMATES Transplantation, 2000, 69, S123.	1.0	2
208	Costimulation blockade and tolerance. Current Opinion in Organ Transplantation, 2002, 7, 7-12.	1.6	2
209	Ability of donor splenocytes with costimulation blockade to induce mixed hematopoietic chimerism and transplantation tolerance. Transplantation Proceedings, 2004, 36, 2423-2424.	0.6	2
210	Prevention Of Acute GvHD During Haplo-BMT: Evaluating The Efficacy Of T-Cell Costimulation Blockade Using A Novel Rhesus Macaque Transplant Model. Biology of Blood and Marrow Transplantation, 2009, 15, 114-115.	2.0	2
211	Managing COVID-19-positive Solid Organ Transplant Recipients in the Community: What a Community Healthcare Provider Needs to Know. Transplantation Direct, 2020, 6, e633.	1.6	2
212	HEMATOPOIETIC CHIMERISM IN THE PRESENCE OF CD40 AND CD28 BLOCKADE LEADS TO PERIPHERAL DELETION OF DONOR REACTIVE T CELLS AND DEVELOPMENT OF DONOR SPECIFIC TRANSPLANTATION TOLERANCE Transplantation, 2000, 69, S240.	1.0	1
213	(2) Targeting the T-cell costimulation pathways allows long-term survival of neonatal porcine islets in diabetic non-human primates. Xenotransplantation, 2007, 14, 178-179.	2.8	1
214	Corticosteroids and methotrexate as adjuvants to costimulation blockade in nonâ€human primate renal transplantation. Clinical Transplantation, 2019, 33, e13568.	1.6	1
215	Islet transplantation, stem cells, and transfusion medicine. Transfusion Medicine Reviews, 2003, 17, 95-109.	2.0	1
216	NK Cells Efficiently Prevent Engraftment of Donor Stem Cells after Tolerigenic Bone Marrow Transplantation Blood, 2005, 106, 3025-3025.	1.4	1

#	Article	IF	CITATIONS
217	Longitudinal Evaluation of Cytopenias in the Renal Transplant Population. Transplantation Direct, 2022, 8, e1339.	1.6	1
218	ROLE OF CD40L IN THE INITIATION, AMPLIFICATION, AND EFFECTOR PHASE OF ALLOIMMUNE RESPONSES Transplantation, 2000, 69, S131.	1.0	0
219	FAS LIGAND PLAYS A CRUCIAL ROLE IN COSTIMULATION BLOCKADE RESISTANT REJECTION Transplantation, 2000, 69, S398.	1.0	0
220	Targeting the ICOS-B7h Costimulatory Pathway Synergizes with Rapamycin to Regulate Alloresponses in Islet Transplantation. Transplantation, 2003, 76, S51.	1.0	0
221	COMBINED CD40/CD28 BLOCKADE SYNERGIZES TO PROMOTE ISLET ALLOGRAFT SURVIVAL IN A NONHUMAN PRIMATE MODEL. Transplantation, 2003, 76, S31.	1.0	0
222	NK cell alloreactivity is an important mediator of costimulation-blockade-resistant rejection during allogeneic transplantation. Biology of Blood and Marrow Transplantation, 2005, 11, 36-37.	2.0	0
223	F.142. Inhibition of T-Cell Activation By CD28 and CD40L Blockade Is Influenced By T-Cell Precursor Frequency. Clinical Immunology, 2006, 119, S100-S101.	3.2	0
224	F.141. A Role for PD-1 in Maintaining Peripheral Tolerance to An Allogeneic Skin Graft. Clinical Immunology, 2006, 119, S100.	3.2	0
225	OR.96. Long-Term Survival of Neonatal Porcine Islet Xenografts in Diabetic Non-Human Primates By Targeting Costimulation Pathways. Clinical Immunology, 2006, 119, S40.	3.2	0
226	INFLUENCE OF DONOR TYPE ON ELDERLY KIDNEY TRANSPLANT SURVIVAL AND ALLOGRAFT FUNCTION. Transplantation, 2008, 86, 116.	1.0	0
227	A novel calcineurin inhibitor– and sirolimus-free anti-LFA-1-based therapy enhances allogeneic islet survival and function in nonhuman primates. Journal of the American College of Surgeons, 2009, 209, S56.	0.5	0
228	Berkeley Sickle Mice Demonstrate CD8- and NK1.1-Dependent Increased Rejection of Allogeneic Hematopoietic Stem Cell Transplants Blood, 2005, 106, 2332-2332.	1.4	0
229	Establishment of Chimerism in Rhesus Macaques through Nonmyeloablative Hematopoietic Stem Cell Transplant and Costimulation Blockade-Based Immunosuppression Blood, 2006, 108, 3202-3202.	1.4	0
230	Apoptotic Cells Break Tolerance Induced by CD40-CD40L Blockade Blood, 2006, 108, 3221-3221.	1.4	0
231	Protective Immunity in Transplant Recipients. FASEB Journal, 2008, 22, 532-532.	0.5	0
232	Great Expectations. American Journal of Transplantation, 2022, , .	4.7	0